Comparison of Outcomes Between Additional Esophagectomy After Noncurative Endoscopic Resection and Upfront Esophagectomy for T1N0 Esophageal Squamous Cell Carcinoma

食管切除术 医学 外科肿瘤学 淋巴结 食管癌 食管鳞状细胞癌 淋巴 外科 胃肠病学 内科学 肿瘤科 癌症 病理
作者
Suguru Maruyama,Akihiko Okamura,Yu Imamura,Jun Kanamori,Yasukazu Kanie,Keita Takahashi,Daisuke Fujiwara,Masayuki Watanabe
出处
期刊:Annals of Surgical Oncology [Springer Nature]
卷期号:28 (9): 4859-4866 被引量:8
标识
DOI:10.1245/s10434-020-09498-z
摘要

Esophagectomy with lymph node dissection is a choice of additional treatment after noncurative endoscopic resection (ER) of T1N0 esophageal squamous cell carcinoma (ESCC). The efficacy and safety of esophagectomy in this situation remain unclear when compared with upfront esophagectomy.We investigated the short- and long-term outcomes of 321 patients with clinical T1N0M0 ESCC who underwent curative esophagectomy, and compared the status of lymph node metastasis, surgical results, and the prognosis between the ER and non-ER groups.The ER group consisted of 57 patients (17.8%), while the non-ER group consisted of 264 patients (82.2%). The incidence of lymph node metastasis was not significantly different between the ER (24.6%) and non-ER groups (30.7%), and there was no significant difference in surgical outcomes between the groups. The distribution of metastatic lymph nodes was very similar between the groups. However, 13 of 14 patients (93%) with lymph node metastasis in the ER group and 63 of 82 patients (77%) with lymph node metastasis in the non-ER group had pN1 disease, while the remaining 18 patients (23%) with lymph node metastasis in the non-ER group had pN2 or N3 disease. Overall and relapse-free survival rates were significantly better in the ER group than in the non-ER group (p < 0.05 and p < 0.01, respectively). To date, no patients in the ER group experienced disease recurrence.Additional esophagectomy is a safe and effective treatment modality for patients after noncurative ER.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
4秒前
某只橘猫君完成签到,获得积分10
5秒前
量子星尘发布了新的文献求助10
7秒前
平安喜乐发布了新的文献求助10
9秒前
江三村完成签到 ,获得积分0
10秒前
结实的芷荷完成签到 ,获得积分10
11秒前
11秒前
系小小鱼啊完成签到,获得积分10
12秒前
jkaaa完成签到,获得积分10
13秒前
16秒前
yofluenza发布了新的文献求助10
17秒前
17秒前
mp5完成签到,获得积分10
19秒前
甜蜜秋白完成签到,获得积分10
19秒前
积极松鼠完成签到,获得积分10
20秒前
LYF完成签到 ,获得积分10
21秒前
无心完成签到,获得积分10
23秒前
iuhgnor完成签到,获得积分10
24秒前
小叙完成签到 ,获得积分10
24秒前
ARIA完成签到 ,获得积分10
25秒前
25秒前
近代完成签到,获得积分10
26秒前
菠萝水手完成签到,获得积分10
26秒前
听山晓月完成签到 ,获得积分10
26秒前
27秒前
兴奋小丸子完成签到,获得积分10
30秒前
31秒前
平安喜乐发布了新的文献求助10
32秒前
科研通AI6.3应助Enomama采纳,获得10
32秒前
高挑的含卉完成签到,获得积分20
32秒前
32秒前
大常完成签到,获得积分10
32秒前
tang应助yofluenza采纳,获得10
33秒前
36秒前
NexusExplorer应助fu采纳,获得10
36秒前
量子星尘发布了新的文献求助10
37秒前
笑点低的凉面完成签到,获得积分10
37秒前
xzx完成签到 ,获得积分10
38秒前
yang完成签到,获得积分10
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Social Work and Social Welfare: An Invitation(7th Edition) 410
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6059127
求助须知:如何正确求助?哪些是违规求助? 7891689
关于积分的说明 16297176
捐赠科研通 5203401
什么是DOI,文献DOI怎么找? 2783957
邀请新用户注册赠送积分活动 1766631
关于科研通互助平台的介绍 1647154